[Skip to Navigation]
October 21, 2020

Improving Outcomes for Patients With Epidermal Necrolysis

Author Affiliations
  • 1Perelman School of Medicine, Department of Dermatology, Department of Medicine, University of Pennsylvania, Philadelphia
  • 2Images in Dermatology Editor, JAMA Dermatology
  • 3Department of Dermatology, Brigham and Women’s Hospital, Harvard University of School of Medicine, Boston, Massachusetts
JAMA Dermatol. 2020;156(12):1289-1290. doi:10.1001/jamadermatol.2020.3655

Epidermal necrolysis (EN), encompassing the spectrum of Stevens-Johnson syndrome and toxic EN, is a rare, severe cutaneous drug reaction with an estimated mortality in modern cohorts of 15% to 23%.1-3 The rarity of the disease makes rigorous prospective clinical research difficult, highlighting the need for multicenter, multinational collaborations as well as iterative efforts to validate and build on prior work.

Add or change institution